Select Equity Group L.P. Invests $903,000 in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Select Equity Group L.P. acquired a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 10,092 shares of the medical equipment provider's stock, valued at approximately $903,000.

Other institutional investors have also recently made changes to their positions in the company. Kestra Investment Management LLC purchased a new stake in shares of Lantheus during the fourth quarter worth approximately $27,000. Summit Securities Group LLC acquired a new position in Lantheus in the fourth quarter valued at approximately $37,000. UMB Bank n.a. raised its holdings in Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after buying an additional 134 shares during the period. Parkside Financial Bank & Trust boosted its position in shares of Lantheus by 49.4% during the fourth quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock worth $76,000 after buying an additional 280 shares during the period. Finally, 1620 Investment Advisors Inc. purchased a new position in shares of Lantheus in the fourth quarter valued at approximately $125,000. 99.06% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have commented on LNTH shares. B. Riley lowered their price target on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a report on Friday, March 21st. Wall Street Zen raised shares of Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Finally, Truist Financial reduced their price objective on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $132.67.

Lantheus Stock Performance

Shares of NASDAQ:LNTH traded down $0.56 during trading on Friday, reaching $74.20. The company had a trading volume of 159,596 shares, compared to its average volume of 985,299. The firm's fifty day moving average is $95.12 and its 200 day moving average is $92.36. The firm has a market capitalization of $5.13 billion, a PE ratio of 12.36 and a beta of 0.23. Lantheus Holdings, Inc. has a twelve month low of $73.11 and a twelve month high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm had revenue of $372.76 million during the quarter, compared to analysts' expectations of $377.37 million. During the same period last year, the business earned $1.69 earnings per share. The business's revenue was up .8% on a year-over-year basis. Equities analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Insider Activity

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares of the company's stock, valued at approximately $41,551,645.65. This trade represents a 10.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the company's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the sale, the chief financial officer now directly owns 113,860 shares in the company, valued at approximately $11,445,207.20. The trade was a 8.07% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 63,109 shares of company stock worth $6,016,046. 1.50% of the stock is owned by corporate insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.